Lead compound targeting human lipocalin 2 or pharmaceutically acceptable salt thereof, and preparation method and application thereof

CN118930459APending Publication Date: 2024-11-12UNIV OF SCI & TECH OF CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310531499.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art lacks effective means for the malignant fluid phenomenon in advanced patients when treating solid tumors, especially the insufficient development of targeted tumor immune inflammatory factors, resulting in limited therapeutic effects.

Method used

Develop a lead compound or a pharmaceutically acceptable salt thereof targeting LCN2, which binds to the LCN2 protein through a specific structure, inhibits its activity, and thus is used in combination with anti-tumor immunotherapy and chemotherapy.

Benefits of technology

It was verified through in vitro and in vivo assays that the compound can effectively bind LCN2, inhibit tumor growth and malignant fluid progression, providing a new anti-tumor treatment strategy and improving the prognosis of solid tumor patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930459A_ABST
    Figure CN118930459A_ABST
Patent Text Reader

Abstract

The invention relates to a lead compound targeting human lipocalin 2 or pharmaceutically acceptable salt thereof as well as a preparation method and application of the lead compound. The lead compound has a structure as shown in a formula (I): # imgabs0 #, wherein R1 is selected from one of C5-C10 alkyl groups and C3-C10 alkyl ether groups; and R2 is selected from one of H and C1-C10 alkyl groups. The lead compound or the pharmaceutically acceptable salt of the lead compound provided by the invention can realize an anti-tumor immunotherapy effect through an inhibition effect on targeted human lipocalin 2.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a lead compound targeting human lipocalin 2 (LCN2, also known as neutrophil gelatinase-associated lipocalin) or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. Technical Background

[0002] Solid tumors such as lung cancer, liver cancer, pancreatic cancer, and colorectal cancer seriously endanger human life and health, and the existing technical means of treatment have limited effects, especially for the cachexia phenomenon that is common in patients with solid tumors in the late stage. There is no targeted treatment method. Both the formation of the tumor immunosuppressive microenvironment and the progression of tumor cachexia are related to immune inflammatory molecules. At this stage, tumor treatment mainly focuses on using targeted drugs to accurately kill tumor cells or activate the body's immune system, and use the immune system to inhibit the development of tumors. If the technology of targeting tumor immune inflammatory factors can be developed to activate anti-tumor immune cells and inhibit the body's nutrient consumption caused by tumor cachexia, it will be expected to further improve the prognosis of patients with solid tumors. LCN2 is a new type of tumor inflammatory factor, which has also been shown to cause the progression of tumor cachexia. Therefore, the development of targeted LCN2 inhibitors is an important direction for improving the prognosis of existing solid tumors. Summary of the invention

[0003] In view of this, the main purpose of the present invention is to propose a lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof and a preparation method and application thereof, in order to at least partially solve at least one of the above-mentioned technical problems.

[0004] In order to achieve the above object, as one aspect of the present invention, a lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof is provided, wherein the lead compound has a structure shown in the following formula (I):

[0005] Wherein, R1 is selected from a combination of one or more of C5-C10 alkyl and C3-C10 alkyl ether; and R2 is selected from one of H and C1-C10 alkyl.

[0006] As another aspect of the present invention, a method for preparing the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof is provided, comprising the following steps:

[0007] Compound (1) is reacted with R1-OTs to generate compound (2),

[0008]

[0009] The compound (2) is reacted with an aminoguanidine acid addition salt to generate the above-mentioned lead compound,

[0010]

[0011] As another aspect of the present invention, a pharmaceutical composition is provided, comprising the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0012] As another aspect of the present invention, there is provided a use of the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof in the preparation of a drug for anti-tumor immunotherapy.

[0013] As another aspect of the present invention, there is provided a use of the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for combined anti-tumor chemotherapy and immunotherapy.

[0014] As another aspect of the present invention, provided is a use of the lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof in the preparation of a drug for inhibiting LCN2.

[0015] Based on the above technical solution, it can be known that the lead compound targeting LCN2 of the present invention or its pharmaceutically acceptable salt and its preparation method and application have one or part of the following beneficial effects:

[0016] The lead compound or a pharmaceutically acceptable salt thereof provided by the present invention has been determined to target LCN2 and to bind to LCN2 relatively stably through in vitro affinity tests, and has been verified through in vivo model tests that the interaction between the two can effectively inhibit tumor growth. It can be seen that the lead compound or a pharmaceutically acceptable salt thereof of the present invention can achieve an anti-tumor immunotherapy effect by inhibiting LCN2. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The expression of LCN2 in cancer tissues of patients with pan-solid tumors obtained by the present invention according to statistics of the TCGA (The cancer genome atlas) database is shown;

[0018] Figure 2 The construction of the prokaryotic recombinant expression vector pET28a-LCN2 in Example 1 of the present invention, the expression, purification and determination results of the human LCN2 recombinant protein are shown, wherein a is the construction model of pET28a-LCN2, b is the expression amount of the LCN2 protein under different induction conditions, c is the PAGE electrophoresis purity result of the purified LCN2, and d is the Western Blot identification result of the purified LCN2 protein;

[0019] Figure 3The results of the test on the interaction between the LCN2 protein and the compound SMD in Example 3 of the present invention are shown, wherein A is a curve showing the relationship between the dissolution temperature of the LCN2 protein and the concentration of the compound SMD / SEM obtained based on the thermal shift assay, and B is an isothermal calorimetric titration curve of the LCN2 protein-SMD / SEM interaction;

[0020] Figure 4 The mouse tumor model treated with the compound SMD in Example 5 of the present invention is shown, wherein A is the tumor tissue weight of LLC cell line tumor-bearing mice, B is the tumor tissue weight of 4T1 cell line tumor-bearing mice, C is the tumor tissue weight of MC38 cell line tumor-bearing mice, and D is the tumor tissue weight of CT26 cell line tumor-bearing mice;

[0021] Figure 5 The figure shows that the compound SMD in Example 6 of the present invention alleviates tumor cachexia in mice, wherein A is the weight of the mouse after removing the tumor tissue, B is a physical picture of the white fat iWAT tissue in the inguinal part of the mouse, C is the weight of the iWAT tissue in the inguinal part of the mouse, and D is the HE staining result of the gastrocnemius Gast tissue of the mouse. DETAILED DESCRIPTION

[0022] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0023] In the process of implementing the present invention, the expression of LCN2 gene was searched using the international authoritative cancer genome atlas database. Figure 1 The expression of LCN2 in cancer tissues of patients with pan-solid tumors obtained by the present invention according to the statistics of TCGA database is shown. Figure 1 As shown, it was found that in typical solid tumors, including cervical cancer, colorectal cancer, pancreatic cancer, gastric cancer, lung cancer and other patient tumor tissues, the LCN2 gene was significantly highly expressed compared with their adjacent cancer tissues. Further studies have shown that knocking down the LCN2 gene in animal models can inhibit the growth of tumor cells in vitro and in vitro, from which it is inferred that LCN2 is an important tumor treatment target, and blocking the LCN2 protein is beneficial to inhibit tumor growth. On this basis, drug design was carried out based on the structure of LCN2, and it was determined that some aromatic ring compounds or aromatic heterocyclic compounds containing guanidine substitutions have the potential activity of inhibiting LCN2. Further experiments have verified that the lead compound provided by the present invention can be more stably bound to LCN2, thereby effectively inhibiting tumor growth, and can be used in drugs for anti-tumor immunotherapy.

[0024] Specifically, according to some embodiments of the present invention, a lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof is provided, wherein the lead compound has a structure as shown in the following formula (I):

[0025] Wherein, R1 is selected from one of C5-C10 alkyl and C3-C10 alkyl ether; R2 is selected from one of H and C1-C10 alkyl.

[0026] According to the embodiments of the present invention, the lead compound represented by the above formula (I) has a strong binding force with the LCN2 protein, thereby exerting an inhibitory effect on the expression of the LCN2 protein, and has great application prospects in anti-tumor immunotherapy drugs.

[0027] According to an embodiment of the present invention, the C1-C10 alkyl group may be a C1-C10 straight-chain alkyl group or a C1-C10 branched-chain alkyl group, and examples of the C1-C10 alkyl group include: methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. Correspondingly, the C5-C10 alkyl group may be a C5-C10 straight-chain alkyl group or a C5-C10 branched-chain alkyl group.

[0028] According to an embodiment of the present invention, the C3~C10 alkyl ether group can be a monoether or polyether containing 1~5 ether groups, 2~6 C1~C6 alkyl groups, and the connection site is located on the C1~C6 alkyl group. Examples of C3~C10 alkyl ethers include: 2-methoxyethyl, 2-(2-methoxyethoxy)ethyl, etc.

[0029] According to an embodiment of the present invention, R1 is preferably selected from n-hexyl, n-heptyl, n-octyl, It has suitable drug solubility and affinity for targeting LCN2.

[0030] According to an embodiment of the present invention, R2 is preferably selected from H, methyl or ethyl, has affinity for targeting LCN2, and has a relatively simple structure, which is conducive to the preparation of the compound.

[0031] According to an embodiment of the present invention, the lead compound is preferably selected from the structures shown in the following SMD-1 to SMD-4, but these compounds are only representative:

[0032]

[0033] According to an embodiment of the present invention, the pharmaceutically acceptable salt of the lead compound is an acid addition salt of the lead compound, and the acid addition salt of the lead compound of the present invention can be prepared by reacting the free base form of the lead compound with a pharmaceutically acceptable inorganic or organic acid. Preferably, the acid addition salt of the lead compound includes, but is not limited to, hydrochloride, carbonate, sulfate, hydrobromide or phosphate, etc.

[0034] According to an embodiment of the present invention, there is also provided a method for preparing the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof, comprising the following steps:

[0035] Step A: reacting compound 1 with R1-OTs 1a to generate compound 2, as shown in the following formula (A1);

[0036]

[0037] Step B: Compound 2 is reacted with aminoguanidine acid addition salt 2a to generate a lead compound I, specifically represented by the following formula (B1).

[0038]

[0039] According to an embodiment of the present invention, step A specifically comprises: dissolving compound 1, R1-OTs 1a and a base in an organic solvent, and reacting at 60-120° C. (eg 80° C., 100° C., etc.) for 8-12 hours (eg 10 hours, etc.).

[0040] More specifically, the base may be, for example, an inorganic base or an organic base, preferably potassium carbonate, which is conducive to the reaction. The organic solvent may be, for example, N,N-dimethylformamide (DMF), which can dissolve the reactants.

[0041] According to an embodiment of the present invention, step B specifically comprises: dissolving compound 2 and aminoguanidine acid addition salt in an organic solvent, and reacting at 60-120° C. (eg 80° C., 100° C., etc.) for 15-20 hours (eg 16 hours, 18 hours, etc.).

[0042] More specifically, the aminoguanidine acid addition salt may be, for example, aminoguanidine hydrochloride, aminoguanidine carbonate, aminoguanidine sulfate, aminoguanidine hydrobromide or aminoguanidine phosphate, etc. The organic solvent may be, for example, acetonitrile or tetrahydrofuran, etc., which can dissolve the reactants.

[0043] According to an embodiment of the present invention, there is further provided a pharmaceutical composition, comprising the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0044] According to an embodiment of the present invention, the above-mentioned pharmaceutical composition can be formulated into several dosage forms according to the mode of administration, such as oral preparations (such as tablets, capsules, solutions or suspensions); injectable preparations (such as injectable solutions or suspensions, or injectable dry powders, which can be used immediately by adding injection water before injection); topical preparations (such as ointments or solutions).

[0045] According to the embodiments of the present invention, the carrier used in the pharmaceutical composition of the present invention is a common type available in the pharmaceutical field, including: binders, lubricants, disintegrants, solubilizers, diluents, stabilizers, suspending agents, pigments, flavoring agents, etc. for oral preparations; preservatives, solubilizers, stabilizers, etc. for injectable preparations; bases, diluents, lubricants, preservatives, etc. for local preparations. The pharmaceutical preparation can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically).

[0046] According to an embodiment of the present invention, there is also provided a use of the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof in the preparation of a drug for anti-tumor immunotherapy, especially a drug for immunotherapy of subcutaneous lung cancer tumors or subcutaneous colorectal cancer tumors.

[0047] According to an embodiment of the present invention, there is also provided a use of the above-mentioned lead compound targeting LCN2 or a pharmaceutically acceptable salt thereof in the preparation of a drug for combined anti-tumor chemotherapy and immunotherapy.

[0048] According to an embodiment of the present invention, there is further provided a lead compound or a pharmaceutically acceptable salt thereof for use in preparing a drug for inhibiting LCN2.

[0049] The above-mentioned lead compound inhibits LCN2 and thus exerts an anti-tumor immunotherapy effect.

[0050] The technical scheme of the present invention is further described below by specific examples in combination with the accompanying drawings. It should be noted that the following specific examples are only used as examples, and the protection scope of the present invention is not limited thereto. The drugs or reagents used in the following examples are all commercially available or homemade by known preparation methods. The methods used in the following examples, such as Western blot, are all well-known methods in the art and can be carried out by description in textbooks or relevant documents, and will not be repeated here.

[0051] Example 1: Construction of prokaryotic recombinant expression vector pET28a-LCN2, expression, purification and determination of human LCN2 recombinant protein

[0052] The full-length LCN2 gene was artificially synthesized, and a 6×His-Tag was introduced at the N-terminus. First, the pET28a(+) plasmid was linearized using restriction endonucleases Not I and Xho I, and the PCR product of the LCN2 gene was treated with these two enzymes to make its two ends sticky. Finally, the LCN2 gene was connected to the pET28a(+) vector using T4 ligase to successfully construct the prokaryotic expression plasmid of LCN2. The gene was transferred into DH5α competent cells, and positive clones were screened for DNA sequencing identification. The sequencing results showed that the recombinant expression vector pET28a-LCN2 was successfully constructed. The construction process of the prokaryotic recombinant expression vector pET28a-LCN2 is as follows: Figure 2 As shown in a.

[0053] In order to obtain LCN2 protein (uniprot: P80188), different concentrations of isopropyl β-D-Thiogalactoside (IPTG) (0mM, 0.1mM, 0.2mM, 0.4mM) were used to induce the expression strain containing the synthetic LCN2 gene amplified to the logarithmic phase, and samples were taken before induction, 2h after induction, and 4h after induction. Through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE electrophoresis) and Coomassie brilliant blue staining of the whole bacteria, it was found that within a certain range, as the IPTG concentration and induction time increased, the expression of proteins of corresponding sizes also increased and was significantly different from impurity proteins. At the same time, it was also found in the control group that the expression bacteria had background expression of the target protein, such as Figure 2 b.

[0054] The induced expression bacterial solution was further ultrasonically lysed and centrifuged at high speed to obtain a supernatant and a precipitate containing inclusion bodies. The supernatant was passed through a nickel column and gradient eluted with eluents containing different concentrations of imidazole. After obtaining the purified protein solution, the recombinant LCN2 protein solution was concentrated by an ultrafiltration tube and further purified using molecular sieves. Finally, an SDS-PAGE experiment was performed to detect the purity of the protein, and it was found that the purity of the purified protein was high, such as Figure 2 c.

[0055] In order to verify whether the protein is recombinant human LCN2 protein, the sample was tested by Western Blot. The primary antibody used was Anti-His tag. The result showed clear bands, such as Figure 2 d. This proves that the recombinant LCN2 protein was successfully obtained.

[0056] Example 2: Synthesis and identification of SMD compounds

[0057]

[0058] Compound 1-1 1,1′-(5-amino-1,3-phenyl)di(ethyl-1-one) (177 mg, 1 mmol, 1.00 eq), compound 1a (270 mg, 1 mmol, 1.00 eq) and K2CO3 (165 mg, 1.2 mmol, 1.20 eq) were dissolved in DMF (2 mL). The reaction solution was stirred at 80° C. for 8 hours. After the reaction was completed, the reaction solution was poured into water (20.0 mL) and extracted with dichloromethane. The dichloro organic phase was first washed with a saturated sodium bicarbonate aqueous solution (20.0 mL), then washed with brine (20.0 mL), and finally dried with anhydrous sodium sulfate. The dichloro organic phase was filtered and concentrated in vacuo to obtain compound 2-1 (crude, 1.00 eq).

[0059] Compound 2-1 (crude, 1.00eq) and 2a (264mg, 2.4mmol, 2.40eq, HCl) were dissolved in a mixed solvent of acetonitrile and tetrahydrofuran (8.0mL) and stirred at 80°C for 16 hours. After the reaction was completed, the reaction solution was cooled to 20°C, the solid was filtered, and rinsed with ethanol (10.0mL). The crude product was dissolved in ethyl acetate and slurried at 20°C for 30 minutes to obtain compound SMD (103.6mg, 0.245mmol, 24.5% yield, 94.8% purity).

[0060] The structure and purity of compound SMD were identified by LC-MS / MS and H-NMR, and it was confirmed that the target compound SMD was obtained.

[0061] Example 3: Determination of the binding force between SMD and LCN2

[0062] Thermal shift assay (TSA) was used to determine the interaction between LCN2 protein and SMD prepared in Example 2, with SEM (Semamod, CAS: 352513-83-8) as a positive control. The thermal shift assay was performed using a real-time fluorescence quantitative PCR system (Roche LightCycler 480) melting curve program with a temperature increment of 0.01°C and a temperature range of 25-95°C. All reactions were performed in a final volume of 20 μL and were assayed in a 384-well plate using a 1:5000 dilution of 5000×SYPRO orange stock solution (Sigma-Aldrich) and diluted to 10 μM LCN2 recombinant protein in a buffer containing 20 mM Tris. Different concentrations of compounds (5 μm-100 μm) were added to the reaction to evaluate the thermal stability of LCN2 protein binding to two small molecules. The real-time fluorescence quantitative PCR system software (Roche LightCycler480) was used to construct the positive derivative (d(F) / dT) curve and calculate the melting temperature of the protein unfolding transition (Tm), as shown in Figure 3 A, The results show that both SMD and SEM can enhance the thermal stability of LCN2 protein, proving that both directly interact with LCN2 protein, and SMD has a higher binding affinity with LCN2 protein than SEM.

[0063] Isothermal calorimetric titration (ITC) was used to determine the interaction between proteins and SMDs. The dialyzed protein and small molecule solvent were placed into a 20 mM Hepes buffer system and the pH was adjusted to be consistent. The PEAQ-ITC isothermal titration microcalorimeter (MicroCal) was turned on and the sample loading needle and the bottom pool were rinsed with buffer. 20 μM protein buffer was added to the bottom pool, bubbles were removed, and 400 μM small molecule inhibitors were added dropwise. The reaction exotherm was detected, the titration curve was fitted, and the binding constant Ka between LCN2 and the two compounds was determined based on the slope at the midpoint of the jump in the titration curve. SMD 1.25 μM and Ka SEM is 1.67 μM, such as Figure 3 B. It is proved again that both compounds have direct and stable interactions with LCN2 protein, and SMD has a stronger binding effect on LCN2 protein than the known SEM.

[0064] Example 4: Solubility determination of SMD

[0065] 5% glucose injection is a common intravenous drip solvent for fluid replacement in tumor patients, so determining the solubility of the two compounds in this solution is of great significance for the choice of administration method. Weigh 10 mg of SMD and SEM fixed powder compounds respectively, add 0.1 mL of 5% glucose injection each time until it is completely dissolved at room temperature, and shake to accelerate dissolution during the period. 10 mg SMD can be dissolved to a clear state when adding the third 0.1 mL of 5% glucose injection, that is, 10 mg SMD is completely dissolved in 0.3 mL 5% glucose injection, and is stable within 8 hours. It proves that the solubility of SMD in 5% glucose injection at room temperature is less than 33.33 mg / mL. 10 mg SEM can be dissolved to a clear state when adding the eightieth 0.1 mL of 5% glucose injection, that is, 10 mg SEM is completely dissolved in 8 mL 5% glucose injection, and is stable within 8 hours. It proves that the solubility of SEM in 5% glucose injection at room temperature is less than 1.25 mg / mL. The above results prove that at room temperature, the solubility of SMD in 5% glucose injection is much higher than that of SEM, and SMD is more suitable for intravenous administration after being dissolved in 5% glucose injection.

[0066] Example 5: Testing of anti-tumor activity by tail vein administration of SMD

[0067] Order several B6 mice (Slack), and inoculate LLC lung cancer cell line, 4T1 breast cancer cell line, MC38 colon cancer cell line, CT26 colon adenocarcinoma cell line (2×10 5 The mice were randomly divided into a control group (GS 125 μL 5% glucose injection / mouse) and a treatment group (SMD 10 mg / kg / 125 μL 5% glucose injection / mouse). The drugs were injected into the tail vein once every three days for a total of 5 times. The 28th day after the start of treatment was the end point of the experiment. The tumor tissues were collected and weighed at the end point of the experiment. Figure 4 A to D; The experimental results show that in the four mouse solid tumor subcutaneous tumor models of LLC, 4T1, MC38 and CT26, tail vein administration of SMD can effectively inhibit tumor growth, indicating that SMD has the ability to significantly inhibit the growth of pan-solid tumors in mice.

[0068] Example 6: SMD inhibits cachexia progression in mouse tumor models

[0069] The high-dose LLC cell line subcutaneous tumor model is a classic model for inducing tumor cachexia in mice. Sufficient LLC cells were cultured to an appropriate density, and after trypsin digestion, the concentration of LLC single cell suspension was adjusted to 5×10 in phosphate buffer according to the counting results. 6LLC cells / 200 μL. The hair on the armpit side of 8-week-old male B6 mice was shaved with a mouse shaver, and the cells were aspirated with a 1 mL insulin needle. The needle was inserted parallel to the mouse skin, the skin was lifted to confirm that the needle was in the subcutaneous position of the mouse, and the cells were subcutaneously injected into the mouse. Each mouse was injected with 5×10 6 LLC cells / 200 μL. After the third week of LLC cell inoculation, the weight changes, adipose tissue and muscle tissue weight and atrophy of mice were evaluated to assess the progression of tumor cachexia in mice.

[0070] SMD administration via tail vein alleviates the progression of tumor cachexia in mice. The tumors were randomly divided into a control group (GS 125μL 5% glucose injection / mouse) and a treatment group (SMD 10mg / kg / 125μL 5% glucose injection / mouse), and the drug was administered via tail vein injection once every three days until the end of the experiment in the third week of cell inoculation. The experimental results showed that the net weight of mice in the SMD treatment group after removing the tumor tissue was significantly higher than that in the control GS group ( Figure 5 A); The actual image and weighing results of the white fat iWAT tissue in the inguinal area of ​​mice showed that the fat weight of the SMD treatment group was significantly higher than that of the control GS group ( Figure 5 B / C); Typical HE staining results of gastrocnemius Gast tissue of mice also showed that the muscle tissue atrophy in the SMD treatment group was significantly better than that in the control GS group ( Figure 5 D). The above results indicate that tail vein administration of SMD can effectively alleviate the progression of tumor cachexia in mice.

[0071] It can be seen that through mouse model experiments, it was found that SMD can inhibit the growth of various subcutaneous tumors and alleviate the progression of tumor cachexia in mice, indicating that the combination of SMD and LCN2 can inhibit LCN2, which is beneficial to the realization of anti-tumor immunotherapy.

[0072] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A lead compound targeting human lipocalin 2 or a pharmaceutically acceptable salt thereof, wherein the lead compound has a structure as shown in the following formula (I): in, R1 is selected from one of C5-C10 alkyl and C3-C10 alkyl ether groups; R2 is selected from H, C1-C10 alkyl.

2. The lead compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from n-hexyl, n-heptyl, n-octyl, 3. The lead compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from H, methyl or ethyl.

4. The lead compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein: The pharmaceutically acceptable salts of the lead compound include hydrochloride, carbonate, sulfate, hydrobromide or phosphate.

5. A method for preparing a lead compound targeting human lipocalin 2 or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 4, comprising the following steps: Compound (1) is reacted with R1-OTs to generate compound (2), The compound (2) is reacted with an aminoguanidine acid addition salt to generate the lead compound, 6. The preparation method according to claim 5, wherein: The step of reacting compound (1) with R1-OTs comprises: The compound (1), R1-OTs and a base are dissolved in an organic solvent and reacted at 60-120° C. for 8-12 hours.

7. The preparation method according to claim 5, wherein: The step of reacting compound (2) with an aminoguanidine acid addition salt comprises: Dissolving the compound (2) and the aminoguanidine acid addition salt in an organic solvent, and reacting at 60 to 120° C. for 15 to 20 hours; The aminoguanidine acid addition salt is preferably aminoguanidine hydrochloride, aminoguanidine carbonate, aminoguanidine sulfate, aminoguanidine hydrobromide or aminoguanidine phosphate.

8. A pharmaceutical composition comprising the lead compound targeting human lipocalin 2 according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. Use of a lead compound targeting human lipocalin 2 or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 4 in the preparation of a medicament for anti-tumor immunotherapy, or in the preparation of a medicament for the combination of anti-tumor chemotherapy and immunotherapy. 10 . Use of the lead compound targeting human lipocalin 2 or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in the preparation of a medicament for inhibiting human lipocalin 2.